Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.

Grem, J L; Hoth, D F; Leyland-Jones, B; King, S A; Ungerleider, R S; Wittes, R E

Grem, J L; Hoth, D F; Leyland-Jones, B; King, S A; Ungerleider, R S; Wittes, R E.

Affiliation

Grem JL; Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892.

J Clin Oncol ; 6(2): 351-79, 1988 Feb.

Article in En | MEDLINE | ID: mdl-3276827

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia, Lymphoid/drug therapy; Podophyllotoxin/analogs & derivatives; Teniposide/therapeutic use; Combined Modality Therapy; Cytarabine/administration & dosage; Drug Administration Schedule; Humans; Leukemia, Lymphoid/mortality; Teniposide/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Podophyllotoxin / Teniposide / Leukemia, Lymphoid / Antineoplastic Combined Chemotherapy Protocols Limits: Humans Language: En Journal: J Clin Oncol Year: 1988 Document type: Article Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links